ArticleJournal of racial and ethnic health disparities2026
Chronic Health Conditions and Uptake of COVID-19 Testing and Vaccination Among Native Americans in Oklahoma in the RADx-UP Consortium.
Article in Journal of racial and ethnic health disparities, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Community-engaged Approaches to Testing in Community and Healthcare Settings for Underserved Populations
CATCH-UP Vaccines: Extension of Community - Engaged Approaches to Testing in Community and Healthcare Settings for Underserved Populations
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
introductionAmerican Indian/Alaska Native (AI/AN) individuals were disproportionately affected by the COVID-19 pandemic. We aimed to evaluate whether the presence of chronic health conditions (CHC) impacted COVID-19 testing and vaccination for AI/AN people in Oklahoma.
methodsWe pooled survey data that included adult AI/AN participants weighted using the 2022 American Community Survey. We used modified Poisson regression to estimate prevalence proportion ratios (PPR) and 95% confidence intervals (CI) accounting for weighting, multiple imputation, and confounders to determine whether access to COVID-19 testing and vaccine uptake differed by CHC status.
resultsAmong the 1,139 participants, 62.6% reported being diagnosed with a CHC. The majority reported being tested for COVID-19 (80.6%) and that testing access was easy (81.7%). We observed no association between CHCs and being tested (Adjusted PPR: 1.08, 95% CI: 0.97, 1.19) or testing access (Adjusted PPR: 1.08, 95% CI: 0.95, 1.21). Over half (57%) of participants received a COVID-19 vaccine. Among unvaccinated individuals, 9.7% reported they were likely to get a vaccine. While we observed no association between CHCs and vaccine status (Adjusted PPR: 1.08, 95% CI: 0.90, 1.27), unvaccinated individuals with a CHC reported they were more likely to get a vaccine compared to individuals with no CHC (Adjusted PPR: 1.81, 95% CI: 1.01, 2.62). DISCUSSION: The AI/AN population is at higher risk of developing CHC, which increases the risk for severe COVID-19. Thus, evaluating barriers to accessing testing and vaccines is important to improve outcomes. This analysis is important in supporting programs for seasonal epidemics and future pandemics. TRIAL REGISTRATION NUMBERS: NCT04870307, NCT05236270.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.